Lei Wang is an accomplished professional in the field of translational medicine, currently serving as Translational Medicine Lead at Sanofi since December 2021. Previously, Lei worked as Principal Scientist in Translational Research and Early Development at Ikena Oncology from August 2019 to December 2021. Lei's prior experience includes roles as Senior Scientist/Scientist II at Syndax Pharmaceuticals, where responsibilities encompassed analyzing clinical correlative data, developing predictive biomarkers, and managing clinical pharmacology assay development. Earlier experience includes a position as Scientist at Enumeral Biomedical Holdings, Inc., focusing on antibody discovery and immunology assays, and a postdoctoral fellowship at Dana-Farber Cancer Institute, where Lei investigated the synergy of epigenetic drugs with CTLA-4 blockade in cancer models. Education includes a Ph.D. in Biochemistry, Molecular and Cellular Biology, and Oncology from Harvard Medical School and a Master’s degree in Biochemical Engineering from Shanghai University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices